Acrivon posts Q2 2023 net loss of $13.9M; cash $151M funds ops into 2025

Acrivon Therapeutics, Inc.

2023-Q2 EPS reported -$1.22

Net loss $13.9M vs $5.8M in Q2 2022; R&D expenses $10.5M, up from $4.1M.
Cash, equivalents and marketable securities $151.0M as of June 30, 2023.
Registrational-intent Phase 2 trial of ACR-368 enrolling; initial data expected H2 2023.
FDA granted two Fast Track designations for ACR-368 in OncoSignature-positive ovarian and endometrial cancers.
Appointed Charles Baum to board and Adam Levy as SVP IR and corporate affairs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acrivon Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $13.9 million.

Period: the second quarter ended June 30, 2023
Net income: $13.9 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended June 30, 2023 was $13.9 million

View on SEC.gov

Browse all earnings releases →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-209745

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.